H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Coherus Biosciences to $26 from $30 and keeps a Buy rating on the shares. The analyst expects catalysts for Udenyca and Cimerli to drive growth in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences reports Q4 EPS (60c), consensus (84c)
- Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
- Coherus Biosciences announces FDA approved UDENYCA autoinjector
- Coherus BioSciences to Present at Upcoming Investor Conferences in March
- Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
